Tracy Li, PhD, serves as the Senior Director of Precision Medicine and Innovative Strategies at Merck, where the focus is on leading pan-tumor precision medicine initiatives in oncology since 2024. Prior experience includes positions at Johnson & Johnson Innovative Medicine, where Tracy successfully launched RYBREVANT® and ZYTIGA® while enhancing payer considerations in early development programs. At Rutgers School of Public Health, Tracy contributed as an adjunct assistant professor, fostering collaboration between academia and industry. Previous roles also encompass senior leadership in health economics and outcomes research at Daiichi Sankyo and Bristol Myers-Squibb, where significant contributions to drug approval processes were made. Early research work was conducted at the University of Medicine & Dentistry of New Jersey, focusing on epidemiologic studies and securing government grants. Educational credentials include a PhD in Epidemiology from Rutgers University and various advanced degrees in Economics and Statistics.
This person is not in the org chart
This person is not in any teams
This person is not in any offices